Laronidase
CAS 210589-09-6Biologic
Overview
Laronidase is an enzyme replacement therapy used to treat patients with mucopolysaccharidosis I (MPS I), a lysosomal storage disorder caused by the deficiency of the enzyme alpha-L-iduronidase. It works by breaking down glycosaminoglycans that build up in cells over time, alleviating symptoms associated with the disorder.
Therapeutic areas
Genetic DisordersMetabolic Disorders
Verified Supplier Partner
Do you supply Laronidase? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.